title: Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
abstract: Our objective was to compare the onset and duration of a single dose of pantoprazole or omeprazole on maximally stimulated gastric acid secretion. This double-blind, randomized, placebo-controlled study involved 36 healthy adults and utilized continuous pentagastrin infusion to stimulate acid secretion after administration of pantoprazole, 40 mg, omeprazole, 20 mg, or placebo. Gastric aspirates were collected over 24 hr and analyzed for volume, pH, and hydrogen ion concentration, and gastric acid outputs (GAO) were calculated. Comparison between GAO and intragastric pH was performed. Pantoprazole resulted in significantly greater inhibition of GAO than omeprazole. Mean cumulative 24-hr GAO was 164 +/- 130 mEq for pantoprazole versus 283 +/- 159 mEq for omeprazole (P = 0.031). Pantoprazole patients reached and maintained GAO levels below the 10-mEq/hr threshold at 5.7 hr, whereas omeprazole patients never reached this threshold. We conclude that pantoprazole significantly suppressed gastric acid secretion compared to omeprazole. Comparisons between pH and GAO showed that GAO was a more appropriate measure of gastric acid secretion than intragastric pH.
authors.affiliation: Clinical Applications Laboratories, Inc., San Diego, California 92103, USA. vijjilucky@hotmail.com
authors.forename: Vijaya S
authors.initials: VS
authors.lastname: Pratha
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Hogan
authors.forename: James R
authors.initials: JR
authors.lastname: Lane
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Williams
authors.forename: Michael S
authors.initials: MS
authors.lastname: Burton
authors.forename: Richard B
authors.initials: RB
authors.lastname: Lynn
authors.forename: Robyn G
authors.initials: RG
authors.lastname: Karlstadt
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000077402:Pantoprazole; D010418:Pentagastrin / Q000494:pharmacology*; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D012016:Reference Values; D013270:Stomach / Q000187:drug effects; D013454:Sulfoxides / Q000494:pharmacology*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D000077402:Pantoprazole; D010418:Pentagastrin; D009853:Omeprazole